“Moving to our Diabetes franchise, sales declined by 12% in the quarter. This was consistent with our 2015, 2018 guidance. Similar to prior quarters, we achieved good growth in Emerging Markets and stable sales in Europe, but this was more than offset by a 30% decline in U.S. sales due to pricing pressure and the loss of Part D business.”
This quote comes from our good friend Olivier during Sanofi’s earnings call which was this past Tuesday. It also explains why we did not get up early Tuesday morning to listen to the call. The fact of the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.